Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Jaguar Health (JAGX) EBIT (2016 - 2025)

Jaguar Health (JAGX) has disclosed EBIT for 11 consecutive years, with -$7.2 million as the latest value for Q3 2025.

  • On a quarterly basis, EBIT changed 0.33% to -$7.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$29.8 million, a 1.42% increase, with the full-year FY2024 number at -$32.8 million, up 4.39% from a year prior.
  • EBIT was -$7.2 million for Q3 2025 at Jaguar Health, up from -$8.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$5.1 million in Q4 2024 to a low of -$11.8 million in Q1 2022.
  • A 5-year average of -$8.5 million and a median of -$8.2 million in 2024 define the central range for EBIT.
  • Peak YoY movement for EBIT: crashed 109.44% in 2021, then soared 44.05% in 2022.
  • Jaguar Health's EBIT stood at -$10.8 million in 2021, then surged by 41.91% to -$6.3 million in 2022, then dropped by 20.22% to -$7.6 million in 2023, then soared by 32.05% to -$5.1 million in 2024, then plummeted by 40.95% to -$7.2 million in 2025.
  • Per Business Quant, the three most recent readings for JAGX's EBIT are -$7.2 million (Q3 2025), -$8.0 million (Q2 2025), and -$9.4 million (Q1 2025).